Clinical Characteristics and Outcomes of Patients With Mpox Who Received Tecovirimat in a New York City Health System.
Christopher VoRustin ZomorodiRichard SilveraLogan BartramLuz Amarilis LugoErna KojicAntonio UrbinaJudith AbergKeith M SigelRachel ChasanGopi PatelPublished in: Open forum infectious diseases (2023)
There were no significant differences in outcomes between people with HIV when evaluated as a whole and patients without immunocompromising conditions. However, mpox infection was associated with higher rates of hospitalization in those with severe immunocompromise, including patients with HIV/AIDS. Treatment with tecovirimat was well tolerated.Key Points: In our mpox cohort, people with HIV had similar rates of recovery and complications as those without HIV or other immunocompromising conditions. Severe immunocompromise was associated with a higher hospitalization rate. Tecovirimat was well tolerated, with minimal side effects.
Keyphrases
- hiv aids
- antiretroviral therapy
- hiv infected
- hiv positive
- human immunodeficiency virus
- hiv testing
- end stage renal disease
- hepatitis c virus
- men who have sex with men
- ejection fraction
- early onset
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- south africa
- metabolic syndrome
- insulin resistance
- type diabetes
- replacement therapy